About This Document
This document maps the current research landscape for hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), Mast Cell Activation Syndrome (MCAS), and their overlap — referred to as the Trifecta.
Each entry documents the study, its authors, methodology, sample size, key finding, funding source, and sample provenance where declared. This transparency allows patients, clinicians, researchers, caregivers, and funders to understand not only what the research shows, but who conducted it and under what conditions.
Understanding the funding and sample relationships between studies and advocacy organisations is standard research literacy. This document presents that information factually and without judgement, as a service to all audiences.
Research gap statements are included throughout. These are not criticisms — they identify where the evidence is thin, where studies have not yet been conducted, and where patient need is not yet matched by research investment. Gaps are opportunities, not failures.
This document is reviewed quarterly. New significant publications will be added at each review cycle.
How to Use This Document
This document is organised by condition first, then by research question. Navigate to the condition most relevant to you, then find the question you want answered.
Conditions covered: hEDS · POTS / Dysautonomia · MCAS · Trifecta Overlap · Long COVID / PASC · Neurodivergence · HαT · Dermatology
Research questions addressed for each condition:
- What causes it? (Genetics, mechanism, biomarkers)
- How common is it? (Prevalence, diagnostic delay)
- How do we diagnose it? (Criteria, biomarkers, tools)
- What treatments work? (Pharmacological, lifestyle)
- Who else gets it? (Comorbidities, overlap)
Companion resources are listed at the end of this document and cover specialist areas in more depth: cardiac and structural assessment, folate and embryology, neurodivergence, and Long COVID.
Section 1: Hypermobile Ehlers-Danlos Syndrome (hEDS)
1A — What Causes It? Genetics
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Gensemer et al. / Norris Lab, MUSC | 2025 | WES, 200 hEDS patients, KLK15 knock-in mouse model | Rare variants in 14/15 KLK genes. KLK15 variant segregates in multiple families. Mouse model recapitulates hEDS features including mitral valve prolapse. Reframes hEDS as matrix remodeling and immune signaling beyond collagen. | MUSC Independent | MUSC Registry |
| Petrucci-Nelson et al. / Norris Lab MUSC | 2025 | GWAS meta-analysis, 1,815 cases, 5,008 controls. UK Biobank + All of Us + MUSC. 6.2 million variants. | First large-scale GWAS of hEDS. Identified genetic associations across three independent cohorts. SLC39A13 identified as top candidate gene. | MUSC Independent | MUSC Registry + UK Biobank + All of Us |
| HEDGE Study — Laukaitis & Hirschhorn | 2025 | Whole genome sequencing, ~1,000 cases, 86 countries. Broad Institute. | No single causative gene found. Rare TNXB variants in small number. KLK15 described as not explaining most cases (preliminary findings — papers expected 2026). | EDS Society funded and led | EDS Society recruited |
| Norris Lab / Sequencing.com collaboration | Ongoing | Whole genome sequencing + clinical phenotype data, de-identified | Potentially the largest genetic study of hEDS and dysautonomia to date. Active recruitment. | MUSC / Sequencing.com | Sequencing.com / MUSC Registry |
Research gap: The KLK-family genetic findings require independent replication in cohorts outside MUSC. The HEDGE preliminary finding that KLK15 does not explain most cases addresses population-level common variants — a different methodological question from the family-based rare variant approach of the Norris Lab. These are not contradictory studies; they ask different questions. Both require ongoing investigation.
1B — What Causes It? Proteomics and Mechanism
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Griggs et al. / Norris Lab, MUSC | 2025 | Mass spectrometry proteomics, 29+41 hEDS patients vs matched controls. ELISA validation. | 35 differentially expressed proteins. 43% involve complement cascade. Significant reductions in C1QA, C3, C8A, C8B, C9. Links KLK-complement pathway to MCAS via C3a/C5a anaphylatoxin generation. | MUSC Independent | EDS Society provided samples (declared in paper methods; not declared in EDS Society social media promotion) |
| Ritelli et al. / University of Brescia | 2025 | Western blotting, fibronectin and collagen fragments, independent Italian cohort | Identified FN and COLLI fragment signature in hEDS/HSD plasma. Proposed first blood test for hEDS. NOTE: Norris Lab attempted replication using same samples and found bands present in all samples including controls — non-replication not yet published independently. | University of Brescia Independent | Independent Italian cohort |
| de Graf et al. / ICR — InVitro Cell Research | 2025 | Proteomics, 700+ participants: 324 hEDS, 33 HSD, 341 controls | Differences in immune system activity, complement proteins, pain signaling, tissue repair. Largest blood-based proteomics study to date at time of publication. | EDS Society funded active collaboration | EDS Society funded and recruited |
Research gap: The Norris Lab non-replication of Ritelli fibronectin findings is clinically significant and has not been formally published as a standalone replication study. Independent replication of biomarker findings across centres is essential before any biomarker is considered validated. The disconnect between the Ritelli finding and the Norris non-replication has not been communicated to the patient community.
1C — How Do We Diagnose It?
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Malfait et al. | 2017 | International classification consensus | Current reference standard 2017 hEDS diagnostic criteria. Three-criterion framework: GJH, systemic features, exclusion of alternatives. Includes MVP and aortic root dilation as cardiovascular features. | EDS Society / International Consortium | Expert consensus |
| Ritelli et al. / University of Brescia | 2024 | Retrospective, 327 patients, 213 families, Italian reference centre | 2017 criteria criticised as too stringent. Advocates for broadening criteria. hEDS and HSD may represent spectrum of one condition. | University of Brescia Independent | Independent Italian cohort |
| Forghani et al. / University of Miami | 2025 | Retrospective, 907 patients referred for hEDS evaluation 2019-2022 | 178/907 (19.6%) met 2017 criteria. Genetic testing identified alternative/additional diagnosis in 47 of those (26.4%). Highlights importance of genetic exclusion. | University of Miami Independent | HCTD Clinic Registry |
| Toronto GoodHope EDS Clinic | 2020 | Retrospective cohort, 131 patients with prior hEDS diagnosis | Only 15% (20/131) of patients with prior hEDS diagnosis met 2017 criteria. Criteria may require refinement. | Independent clinical review | Clinical cohort |
| Tofts et al. | 2023 | Narrative review / consensus | Paediatric joint hypermobility diagnostic framework. Recommends against hEDS diagnosis before biological maturity. | International Consortium | Expert consensus |
Research gap: The 2026 hEDS diagnostic criteria update (Road to 2026) is currently in development. Preliminary findings suggest criteria may incorporate KLK variants, dysautonomia, and MCAS as comorbidities — which would represent a significant paradigm shift. The new criteria are expected late 2026.
1D — How Common Is It?
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Daylor et al. / Norris Lab MUSC | 2025 | Global survey, 3,906 hEDS + 546 HSD participants, 9,258 responses screened | Mean 24 comorbidities in hEDS. Average diagnostic delay 22.1 years. Symptom onset average age 9.3 years. Dermatological issues reported by 99.6% of hEDS participants. | MUSC Independent | MUSC / International survey |
| Halverson et al. | 2023 | Survey, 505 hEDS patients, EDS Society Global Registry | Average 10.45 alternative diagnoses before hEDS. Anxiety, depression, migraines, POTS, IBS most common co-diagnoses. | EDS Society — used EDS Society registry | EDS Society Global Registry |
| Petrucci et al. / MUSC | 2024 | Cluster analysis, MUSC cohort | Identified distinct phenotypic clusters and multimorbidity patterns in hEDS. Supports hEDS as heterogeneous condition. | MUSC Independent | MUSC Registry |
| Wachs et al. / DICE Registry | 2024 | Survey, 2,500+ hEDS patients, DICE Global Registry | 60%+ self-reported POTS. High rates ADHD, heart conditions, GI issues. Self-report bias acknowledged — cannot infer population prevalence. | Independent (patient-led registry) | DICE Registry — self-report |
1E — What Treatments Work?
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Eichinger et al. / MUSC | 2025 | Clinical study, hEDS orthopaedic presentations | Documents orthopaedic manifestations and management approaches in hEDS. | MUSC Independent | MUSC clinical cohort |
| Baeza-Velasco et al. | 2023 | Prospective, 9-week multidisciplinary rehabilitation program | Sustained improvements at 6 months in 6-minute walk test, balance, fatigue, kinesiophobia, quality of life. Strongest evidence for multidisciplinary rehab in hEDS. | Independent | Clinical cohort |
| Aziz et al. / AGA | 2025 | AGA Clinical Practice Update | Clinical guidance for GI symptoms in hEDS with MCAS/POTS. Recommends targeted testing rather than universal screening. Expert review. | American Gastroenterological Association | Expert consensus / literature review |
Research gap: No well-powered randomised controlled trial exists for any pharmacological treatment specifically in hEDS. Treatment recommendations are largely extrapolated from related conditions or based on expert opinion. This is the most significant evidence gap in hEDS clinical management.
Section 2: POTS / Dysautonomia
2A — What Causes It / How Common Is It?
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Miller et al. | 2020 | Cross-sectional, 91 POTS patients at 2018 Dysautonomia International Conference | 31% of POTS patients met 2017 hEDS criteria. 55% had generalised joint hypermobility. First study using 2017 criteria. | Dysautonomia International funded | Conference convenience sample |
| Maxwell et al. | 2025 | Retrospective, 100 young POTS patients | 31% MCAS in POTS+hEDS vs 2% without. Strong trifecta prevalence signal across multiple diagnostic frameworks. | Independent | Clinical cohort |
| Peebles et al. | 2022 | HUT and active stand, 45 young women across hypermobility spectrum | POTS more prevalent in HSD than hEDS on HUT. Challenges inclusion of POTS in hEDS diagnostic criteria based on objective testing alone. | Independent | Clinical cohort |
2B — What Treatments Work?
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Kwok et al. | 2025 | Systematic review, 21 RCTs, 750 patients, 2000-2023 | No well-powered RCTs for any POTS treatment. Beta-blockers, midodrine, ivabradine most studied. Large multicenter trials urgently needed. | Independent | Literature review |
| Frontiers Neurology systematic review | 2025 | Systematic review, oral medications for POTS | Ivabradine and midodrine show highest symptomatic improvement rates. Beta-blockers show largest heart rate reduction. | Independent | Literature review |
| Clinical Autonomic Research systematic review | 2025 | Systematic review, 45 studies, pharmacological and non-pharmacological | Compression garments, physical training, salt supplementation, vagal nerve stimulation as first-line non-pharmacological options. | Independent | Literature review |
| Canadian Cardiovascular Society | 2020 | Position statement | Clinical guidance on POTS management. Reference standard for Canadian practice. | CCS | Expert consensus |
| Lau et al. / University of Adelaide, ADARC | 2026 | State-of-the-art review. Heart, Lung and Circulation. Australian authorship (ADARC, University of Adelaide). | Most recent and comprehensive clinical POTS review. Covers diagnosis, non-pharmacological and pharmacological treatment, multidisciplinary care, diagnostic delay, and specialist access gaps. Flags urgent need for services to meet the growing POTS population. Direct relevance to Australian clinical practice. | Independent. Funded by Dysautonomia International and Standing Up to POTS. | Literature review / expert synthesis |
Research gap: No well-powered RCT exists for any single POTS treatment. Most trials are small, short-duration, and rely on heart rate outcomes rather than patient-reported quality of life. Treatment in hEDS-associated POTS specifically — where vascular and connective tissue mechanisms may differ — has not been separately studied.
Section 3: Mast Cell Activation Syndrome (MCAS)
3A — How Do We Diagnose It?
Two competing diagnostic frameworks exist. This is not a settled question. The choice of framework has direct patient consequences — determining who receives a diagnosis and therefore who receives treatment.
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Valent et al. / ECNM-AIM Consensus-1 | 2012 | International expert consensus | Stricter criteria. Requires objective mediator elevation (tryptase 20%+2 formula within 4 hours of episode). Endorsed by European and US allergy/immunology bodies. Higher specificity, may miss milder presentations. | ECNM / AIM — independent | Expert consensus |
| Afrin & Molderings / Consensus-2 | 2020 | Clinical diagnostic framework | Broader clinical criteria. Emphasises symptom burden and treatment response. Captures more patients. Contested for potential overdiagnosis by Consensus-1 proponents. Best available clinical tool in absence of validated alternatives. | Independent | Clinical experience / literature |
| Gülen et al. / Karolinska | 2024 | Comprehensive criteria update | Reviews challenges in diagnosing MCAS. Supports rigorous application of objective criteria. | Karolinska University Hospital | Clinical review |
| Zaghmout et al. | 2024 | 703 patients with suspected mast cell disorders | Low confirmed prevalence of idiopathic MCAS when strict criteria applied. Important counterpoint to prevalence estimates from broader criteria. | Independent | Clinical cohort |
| ASCIA Position Paper | 2025 | Australian clinical guidance | Australian diagnostic and management guidance for MCAS. Tryptase identified as most accessible validated test in Australia. | ASCIA — Australian peak body | Expert consensus |
Research gap: No outcome validation study has compared Consensus-1 vs Consensus-2 diagnostic frameworks against patient outcomes, treatment response, or quality of life. The criteria debate remains theoretical rather than evidence-based. This is the most urgent diagnostic research need in the MCAS field.
3B — What Treatments Work?
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Molderings, Afrin et al. | 2016 | Literature review, pharmacological treatment options | No therapeutic trials conducted in MCAS. Evidence from small case series only. Stepwise approach: H1/H2 antihistamines, mast cell stabilisers, leukotriene antagonists, targeted adjuncts. | Independent | Literature review |
| Afrin et al. / Am J Med Sci | 2017 | Systematic characterisation, 413 MCAS patients (298 retrospective + 115 prospective) | First large MCAS cohort study. Median age at symptom onset 9 years. Median diagnostic delay 30 years. Documents treatment response patterns. | University of Minnesota / MUSC | Clinical cohort |
| Molderings, Afrin et al. / J Hematol Oncol | 2011 | Foundational clinical guide | Original practical guide for MCAS diagnostic workup and therapeutic options. Consensus-2 framework basis. | Independent | Clinical experience |
| Castells & Butterfield | 2019 | Clinical review | Most widely cited treatment reference. Stepwise approach from antihistamines to mast cell stabilisers. | Independent | Literature review |
| Canadian Consensus Guidelines | 2025 | Practical management approach, Canada | Stepwise diagnosis and management. Includes HαT in differential. | Canadian allergy/immunology bodies | Expert consensus |
| Mast Cell Action UK Primary Care Guide | 2025 | Primary care clinical guidance | Practical UK guidance. Explicitly notes limited evidence base for all current treatments. | Mast Cell Action UK charity | Expert consensus |
Research gap: No randomised controlled trial of any treatment has been conducted in a properly diagnosed MCAS population. This is the single most significant evidence gap across the entire trifecta. Antihistamines — the first-line treatment — have never been tested in an RCT in MCAS despite being recommended with confidence across clinical guidelines.
Section 4: The Trifecta — Overlap and Mechanism
4A — Evidence for Clustering
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Maxwell et al. | 2025 | Retrospective, 100 POTS patients, Frontiers Neurology | 31% MCAS in POTS+hEDS vs 2% without. Odds ratio 32.46. Statistically significant trifecta clustering. | Independent | Clinical cohort |
| Kohn & Chang | 2020 | Literature review | Foundational review of relationship between hEDS, POTS and MCAS. Most cited trifecta review. | Independent | Literature review |
| Afrin et al. / Am J Med Genet | 2016 | Clinical case series | MCAS prevalence in hEDS/HSD patients. Documents trifecta co-occurrence. | Independent | Clinical cohort |
4B — Biological Mechanism
The KLK-complement-mast cell-autonomic pathway (Norris Lab, 2024-2025) provides the first mechanistically coherent biological explanation for the trifecta:
KLK variants → ECM remodeling + complement cleavage (C3/C5) → C3a/C5a anaphylatoxins → mast cell activation → MCAS → autonomic dysregulation via vascular tone → POTS
This pathway connects the Gensemer et al. iScience 2025 genetic findings directly to the Griggs et al. ImmunoHorizons 2025 complement proteomics findings — two independent Norris Lab papers that together describe a complete biological mechanism.
Research gap: The KLK-complement-autonomic pathway is an emerging mechanistic hypothesis based on two peer-reviewed papers and a preprint. It requires independent replication and formal testing in a prospective cohort before it can be considered an established mechanism. It is the most promising mechanistic framework currently available.
Section 5: Long COVID / PASC and the Trifecta
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Davis et al. | 2023 | Major review, Nature Reviews Microbiology | Long COVID affects at least 10% of SARS-CoV-2 infections. 65 million affected globally. POTS and ME/CFS overlap documented. | Independent | Literature review |
| Ganesh & Munipalli | 2024 | Frontiers Neurology | Long COVID and hypermobility spectrum disorders share pathophysiology. COVID as unmasking mechanism for underlying hEDS/HSD. | Independent | Literature review |
| Torok et al. | 2025 | Case-control, USA and UK, BMJ Public Health | Variant connective tissue as independent risk factor for Long COVID. 30% more likely to experience prolonged symptoms. | Independent | Population study |
| Seeley et al. | 2025 | Prospective cohort, Am J Med — Australian POTS Foundation | High incidence of autonomic dysfunction and POTS in Long COVID. Direct Australian relevance. | Australian POTS Foundation collaboration | Clinical cohort |
| Sumantri & Rengganis | 2023 | Clinical review, Asia Pacific Allergy | MCAS mechanism in Long COVID. Mast cell activation as driver of Long COVID inflammatory state. | Independent | Literature review |
| LISTEN Study cohort | 2024 | 578 Long COVID participants, Yale | 28.9% reported new-onset POTS in Long COVID. | NIH / Yale | Prospective cohort |
Research gap: No prospective study has specifically examined the prevalence of undiagnosed hEDS/HSD in Long COVID populations, or the outcomes of MCAS-directed treatment in Long COVID patients with trifecta features. This represents an urgent and feasible research priority.
Section 6: Neurodivergence Overlap
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Cederlöf et al. | 2016 | Nationwide Swedish population cohort | People with EDS 7.4x more likely to have ASD than controls. 5.6x more likely to have ADHD. Foundational epidemiological finding. | Swedish national registry — independent | National population registry |
| Csecs, Iodice, Rae et al. | 2022 | Frontiers Psychiatry | Joint hypermobility links neurodivergence to dysautonomia and pain. Proprioceptive and autonomic mechanism proposed. | Independent | Clinical cohort |
| Glans et al. | 2021 | Large cross-sectional case-control | Generalised joint hypermobility and ASD in adults. Significant association confirmed. | Independent | Clinical cohort |
| Eccles et al. | 2024 | Philosophical Transactions Royal Society B | Proprioceptive surprise model linking hypermobility, neurodivergence, and emotional dysregulation. Key mechanistic paper. | Independent — Dr Jessica Eccles | Clinical research |
| 2025 review of 20 studies | 2025 | Systematic review | Approximately 31% of autistic individuals have elevated hypermobility. | Independent | Literature review |
| Daylor et al. | 2025 | Survey, 3,906 hEDS patients | High rates of ADHD and ASD reported in hEDS survey population. | MUSC Independent | MUSC / International survey |
Research gap: ASD and ADHD diagnostic criteria were developed predominantly from male populations. Females systematically mask presentations, resulting in later diagnosis or no diagnosis. The true prevalence of neurodivergence in hEDS populations — which is predominantly female — is likely underestimated in every study to date. A study using female-specific assessment tools in a well-characterised hEDS population is urgently needed.
Section 7: Hereditary Alpha-Tryptasaemia (HαT)
HαT is caused by increased copy number of the TPSAB1 gene encoding alpha-tryptase. Elevated baseline tryptase results. Affects approximately 5% of Western populations. Important modifier of mast cell-related presentations.
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| Lyons et al. / NIH NIAID | 2019 | Nature Genetics, discovery paper | HαT identified. TPSAB1 copy number gain drives elevated baseline tryptase. Associated with joint hypermobility, GI symptoms, dysautonomia. | NIH / NIAID | NIH cohort |
| Vazquez et al. | 2021 | Genotyping, 266 patients: HSD, hEDS, axial skeletal hypermobility | HαT prevalence in hEDS not significantly higher than general population (4.9%). However HαT modifies phenotype when present — dysphagia and retained primary dentition significantly associated. | Independent | Clinical cohort |
| White et al. / NIH NIAID | 2024 | 250 POTS patients, tryptase genotyping | HαT prevalence in POTS not significantly higher than general population. Autonomic disorders more common in HαT but reverse not true. | NIH / NIAID | Clinical cohort |
| Farley et al. / Mayo Clinic | 2025 | Systematic review, POTS and EDS, MCAS and HαT | Systematic review of MCAS, HαT prevalence in POTS and EDS populations. | Mayo Clinic Independent | Literature review |
Research gap: The interaction between SERPINA1 (AAT) deficiency and TPSAB1 copy number gain has not been formally studied. When AAT — which normally inhibits tryptase — is deficient, elevated tryptase from HαT may act in an environment of impaired inhibition, potentially creating a functional MCAS-like state through a protease/antiprotease imbalance mechanism. This proposed SERPINA1/TPSAB1 functional axis warrants formal biochemical investigation (Finnegan, 2026 — novel hypothesis).
Section 8: Dermatology
Dermatological manifestations are the most prevalent comorbidity domain in hEDS — reported by 99.6% of hEDS patients in the Daylor et al. 2025 global survey. This is the highest prevalence of any of the eight comorbidity domains studied, and yet dermatology research in hEDS is among the thinnest in the literature.
| Study / Authors | Year | Method / Sample | Key Finding | Funder | Sample Source |
|---|---|---|---|---|---|
| JAAD clinical review | 2023 | Systematic review, dermatologic manifestations of EDS subtypes, PubMed + Web of Science | Piezogenic papules, velvety skin, easy bruising, abnormal scarring documented in hEDS. Abnormal scarring present in ~77.7% of all EDS cases. Piezogenic papules show predominance in hEDS. | Independent — American Academy of Dermatology | Literature review |
| Dermatological aspects of hEDS in women | 2021 | PMC review, female-specific | Skin features in hEDS women. Relevance to female-predominant presentation and missed diagnosis. | Independent | Literature review |
| Daylor et al. | 2025 | Survey, 3,906 hEDS patients | Dermatological issues reported by 99.6% hEDS and 93.2% HSD participants — highest prevalence of all eight comorbidity domains. | MUSC Independent | MUSC / International survey |
Research gap: The most prevalent comorbidity domain in hEDS has the thinnest research base. No large prospective dermatological study in a well-characterised hEDS population using 2017 criteria exists. Skin features are in the diagnostic criteria but systematically underweighted in clinical assessment and clinical research design. A dedicated dermatological phenotyping study in hEDS is needed.
Companion Resources — In Development
The following companion resources are planned for development as extensions of this research landscape document. Each covers a specialist area in greater depth.
Companion 1: Cardiac and Structural Assessment in hEDS
Focus areas: Mitral valve prolapse (in 2017 diagnostic criteria), PFO prevalence in hEDS, pectus deformities, aortic root dilation, mitral annular disjunction, atrial septal defects.
Key papers: Paige et al. Stanford (cardiac involvement in hEDS), Norris Lab KLK15 mouse model (MVP finding), Harvey et al. 2025 (Sox9 cardiac valve development).
Core gap: No published study has systematically assessed the full spectrum of cardiac and chest wall structural variants in a well-characterised hEDS population using current 2017 criteria. Cardiac features beyond MVP and aortic root dilation are underscreened and under-documented.
Companion 2: Folate, FRα Autoantibodies and Embryology
Focus areas: Cerebral folate deficiency, FRα autoantibodies in ASD and hEDS, transgenerational heritability, pregnancy complications, miscarriage, neural tube defects, MTHFR interaction.
Key papers: Frye et al. Mol Psychiatry 2013 (foundational FRα/ASD paper), Rossignol & Frye 2021 (systematic review), Quadros et al. 2025 (transgenerational heritability), Qin et al. Nutrients 2023 (pregnancy and miscarriage).
Core gap: The interaction between FRα autoantibodies, MTHFR variants, and SERPINA1 deficiency in multigenerational reproductive failure patterns has not been studied. The transgenerational transmission of FRα autoantibodies and its contribution to neurodevelopmental presentations across generations represents an emerging and clinically important research area.
Companion 3: Neurodivergence — Female Presentation and Missed Diagnosis
Focus areas: ASD/ADHD diagnostic criteria bias toward male presentations, masking in females, late diagnosis patterns, the ConnectED v2.0 neurodivergence assessment methodology.
Key papers: Cederlöf et al. 2016, Csecs et al. 2022, Eccles et al. 2024, Glans et al. 2021.
Core gap: ASD and ADHD diagnostic tools have documented bias toward male presentations. In a condition that is 80%+ female, systematic misidentification of neurodivergence is likely and the true prevalence in hEDS populations is unknown. Assessment tools calibrated for female presentations are needed.
Companion 4: Long COVID, PASC and the Trifecta
Focus areas: COVID-19 as trifecta trigger and unmasking agent, POTS in Long COVID, MCAS mechanism in Long COVID, hEDS as risk factor for Long COVID severity.
Key papers: Ganesh & Munipalli 2024, Torok et al. 2025, Seeley et al. 2025, LISTEN cohort 2024.
Core gap: No prospective study has examined the prevalence of undiagnosed hEDS/HSD in Long COVID populations or tested MCAS-directed treatment in Long COVID patients with trifecta features.
About ConnectED Health Australia
ConnectED Health Australia (www.connectedhealth.au) is a patient-scientist led organisation dedicated to accessible, evidence-based education and clinical tools for people living with hEDS, POTS, MCAS, and Long COVID.
The ConnectED Health Assessment App is a world-first health assessment tool designed to help patients understand and communicate their symptoms to healthcare providers. The assessment is weighted according to rigour of peer-reviewed clinical evidence and has been recognised for its bias-reduction methodology.
Founder:
Tracy Finnegan RN, BAppSci (Integrated Resource Management) | ICU Nurse 1991-2013 | IMB University of Queensland Directors Circle | Harvard Medical School AI in Healthcare (Top 4 of 600) | LEAN Patient Expert, Australian POTS Foundation | Lived experience: hEDS, POTS, MCAS, Long COVID.
This document is for educational purposes only and does not constitute individual medical advice. Always consult a qualified healthcare professional regarding your health circumstances. © Tracy Finnegan / ConnectED Health Australia 2026. All rights reserved.
Document version: April 2026. Next quarterly review: July 2026.